152 related articles for article (PubMed ID: 24019329)
1. Epigenetic approaches for chemosensitization of refractory diffuse large B-cell lymphomas.
Steinhardt JJ; Gartenhaus RB
Cancer Discov; 2013 Sep; 3(9):968-70. PubMed ID: 24019329
[TBL] [Abstract][Full Text] [Related]
2. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.
Clozel T; Yang S; Elstrom RL; Tam W; Martin P; Kormaksson M; Banerjee S; Vasanthakumar A; Culjkovic B; Scott DW; Wyman S; Leser M; Shaknovich R; Chadburn A; Tabbo F; Godley LA; Gascoyne RD; Borden KL; Inghirami G; Leonard JP; Melnick A; Cerchietti L
Cancer Discov; 2013 Sep; 3(9):1002-19. PubMed ID: 23955273
[TBL] [Abstract][Full Text] [Related]
3. Epigenetics: Showing a more sensitive side.
McCarthy N
Nat Rev Cancer; 2013 Oct; 13(10):680. PubMed ID: 24030504
[No Abstract] [Full Text] [Related]
4. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.
Cowan LA; Talwar S; Yang AS
Epigenomics; 2010 Feb; 2(1):71-86. PubMed ID: 22122748
[TBL] [Abstract][Full Text] [Related]
5. Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma.
Li C; Thompson MA; Tamayo AT; Zuo Z; Lee J; Vega F; Ford RJ; Pham LV
Oncotarget; 2012 Mar; 3(3):314-26. PubMed ID: 22447839
[TBL] [Abstract][Full Text] [Related]
6. Integrative genomic analysis of temozolomide resistance in diffuse large B-cell lymphoma.
Leshchenko VV; Kuo PY; Jiang Z; Thirukonda VK; Parekh S
Clin Cancer Res; 2014 Jan; 20(2):382-92. PubMed ID: 24178621
[TBL] [Abstract][Full Text] [Related]
7. Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development.
Kubuschok B; Trepel M
Expert Opin Drug Discov; 2017 Jul; 12(7):733-745. PubMed ID: 28494631
[TBL] [Abstract][Full Text] [Related]
8. [Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors].
Daskalakis M; Blagitko-Dorfs N; Hackanson B; Lübbert M
Pharm Unserer Zeit; 2010 May; 39(3):217-27. PubMed ID: 20425776
[No Abstract] [Full Text] [Related]
9. Genetic polymorphisms of methylenetetrahydrofolate reductase and promoter methylation of MGMT and FHIT genes in diffuse large B cell lymphoma risk in Middle East.
Siraj AK; Ibrahim M; Al-Rasheed M; Bu R; Bavi P; Jehan Z; Abubaker J; Murad W; Al-Dayel F; Ezzat A; El-Solh H; Uddin S; Al-Kuraya K
Ann Hematol; 2007 Dec; 86(12):887-95. PubMed ID: 17712558
[TBL] [Abstract][Full Text] [Related]
10. DNA methyltransferase inhibitors for cancer therapy.
Brueckner B; Kuck D; Lyko F
Cancer J; 2007; 13(1):17-22. PubMed ID: 17464242
[TBL] [Abstract][Full Text] [Related]
11. Correlation between promoter hypermethylation of GSTP1 and response to chemotherapy in diffuse large B cell lymphoma.
Nakamichi I; Tomita Y; Zhang B; Sugiyama H; Kanakura Y; Fukuhara S; Hino M; Kanamaru A; Ogawa H; Aozasa K
Ann Hematol; 2007 Aug; 86(8):557-64. PubMed ID: 17508213
[TBL] [Abstract][Full Text] [Related]
12. MGMT methylation in diffuse large B-cell lymphoma: validation of quantitative methylation-specific PCR and comparison with MGMT protein expression.
Uccella S; Cerutti R; Placidi C; Marchet S; Carnevali I; Bernasconi B; Proserpio I; Pinotti G; Tibiletti MG; Furlan D; Capella C
J Clin Pathol; 2009 Aug; 62(8):715-23. PubMed ID: 19638543
[TBL] [Abstract][Full Text] [Related]
13. Methylation contributes to imbalance of PRDM1α/PRDM1bβ expression in diffuse large B-cell lymphoma.
Zhang YW; Zhang J; Li J; Zhu JF; Yang YL; Zhou LL; Hu ZL; Zhang F
Leuk Lymphoma; 2015; 56(8):2429-38. PubMed ID: 25487076
[TBL] [Abstract][Full Text] [Related]
14. Promoter hypermethylation of PTPL1, PTPN6, DAPK, p16 and 5-azacitidine inhibits growth in DLBCL.
Wang W; Wang J; Li Z; Zhu M; Zhang Z; Wang Y; Jing H
Oncol Rep; 2016 Jan; 35(1):139-46. PubMed ID: 26498513
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of the lamin A/C gene by CpG island promoter hypermethylation in hematologic malignancies, and its association with poor survival in nodal diffuse large B-cell lymphoma.
Agrelo R; Setien F; Espada J; Artiga MJ; Rodriguez M; Pérez-Rosado A; Sanchez-Aguilera A; Fraga MF; Piris MA; Esteller M
J Clin Oncol; 2005 Jun; 23(17):3940-7. PubMed ID: 15867203
[TBL] [Abstract][Full Text] [Related]
16. Array-based profiling of the lymphoma cell DNA methylome does not unequivocally distinguish primary lymphomas of the central nervous system from non-CNS diffuse large B-cell lymphomas.
Vogt J; Wagener R; Montesinos-Rongen M; Ammerpohl O; Paulus W; Deckert M; Siebert R
Genes Chromosomes Cancer; 2019 Jan; 58(1):66-69. PubMed ID: 30284345
[TBL] [Abstract][Full Text] [Related]
17. Investigation of MGMT and DAPK1 methylation patterns in diffuse large B-cell lymphoma using allelic MSP-pyrosequencing.
Kristensen LS; Treppendahl MB; Asmar F; Girkov MS; Nielsen HM; Kjeldsen TE; Ralfkiaer E; Hansen LL; Grønbæk K
Sci Rep; 2013 Sep; 3():2789. PubMed ID: 24071855
[TBL] [Abstract][Full Text] [Related]
18. Methylation silencing CDH23 is a poor prognostic marker in diffuse large B-cell lymphoma.
Cao B; Guo X; Huang L; Wang B; Wang W; Han D; Zhang W; Zhong K
Aging (Albany NY); 2021 Jul; 13(13):17768-17788. PubMed ID: 34252883
[TBL] [Abstract][Full Text] [Related]
19. The epigenetic basis of diffuse large B-cell lymphoma.
Jiang Y; Melnick A
Semin Hematol; 2015 Apr; 52(2):86-96. PubMed ID: 25805588
[TBL] [Abstract][Full Text] [Related]
20. Non-Hodgkin's lymphoma: the old and the new.
Cabanillas F
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S87-90. PubMed ID: 22035756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
